CR20210332A - Anticuerpo que se une a vegf y a il-1beta y métodos de utilización - Google Patents

Anticuerpo que se une a vegf y a il-1beta y métodos de utilización

Info

Publication number
CR20210332A
CR20210332A CR20210332A CR20210332A CR20210332A CR 20210332 A CR20210332 A CR 20210332A CR 20210332 A CR20210332 A CR 20210332A CR 20210332 A CR20210332 A CR 20210332A CR 20210332 A CR20210332 A CR 20210332A
Authority
CR
Costa Rica
Prior art keywords
vegf
methods
1beta
binds
antibody
Prior art date
Application number
CR20210332A
Other languages
English (en)
Inventor
Olaf Mundigl
Sabine Imhof-Jung
Guido Hartmann
Roland Beckmann
Joerg Benz
Stefan Lorenz
Kristian Hobolt Jensen
Stefan Dengl
Hubert Kettenberger
Christian Gassner
Peter Michael Huelsmann
Joerg Moelleken
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20210332A publication Critical patent/CR20210332A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anticuerpos anti-VEGF/anti-IL-1beta y a métodos de utilización de estos.
CR20210332A 2018-12-21 2019-12-20 Anticuerpo que se une a vegf y a il-1beta y métodos de utilización CR20210332A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18215023 2018-12-21
PCT/EP2019/086529 WO2020127873A1 (en) 2018-12-21 2019-12-20 Antibody that binds to vegf and il-1beta and methods of use

Publications (1)

Publication Number Publication Date
CR20210332A true CR20210332A (es) 2021-09-09

Family

ID=64870356

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210332A CR20210332A (es) 2018-12-21 2019-12-20 Anticuerpo que se une a vegf y a il-1beta y métodos de utilización

Country Status (18)

Country Link
US (3) US11130804B2 (es)
EP (1) EP3898671A1 (es)
JP (3) JP7114813B2 (es)
KR (2) KR102652720B1 (es)
CN (1) CN113195531A (es)
AR (1) AR117468A1 (es)
AU (1) AU2019406712B2 (es)
BR (1) BR112021012022A2 (es)
CA (1) CA3123503A1 (es)
CL (1) CL2021001616A1 (es)
CO (1) CO2021008755A2 (es)
CR (1) CR20210332A (es)
IL (1) IL283566A (es)
MX (1) MX2021007421A (es)
PE (1) PE20211294A1 (es)
SG (1) SG11202106198YA (es)
WO (1) WO2020127873A1 (es)
ZA (1) ZA202103643B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7158626B1 (ja) * 2020-09-04 2022-10-21 エフ．ホフマン－ラ ロシュ アーゲー Ｖｅｇｆ－ａ及びａｎｇ２に結合する抗体及び使用方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US830930A (en) 1905-11-22 1906-09-11 E & T Fairbanks & Co Weighing-scale.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
JP4540229B2 (ja) 1998-07-23 2010-09-08 コオペラティ・アヴェベ・ユー・エイ 接着剤組成物
EP2386574A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
US7749753B2 (en) 2002-04-09 2010-07-06 Kyowa Hakko Kirin Co., Ltd Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
WO2003085107A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellules à génome modifié
AU2003239966B9 (en) 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
MXPA05006511A (es) 2002-12-16 2006-02-17 Genentech Inc Variantes de inmunoglobulina y sus usos.
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
EP2264151B1 (en) 2003-01-22 2016-04-20 Roche Glycart AG Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP2357201B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI387602B (zh) 2005-02-07 2013-03-01 Roche Glycart Ag 與上皮生長因子受體（ｅｇｆｒ）結合之抗原結合分子，編碼該抗原結合分子之載體及其用途
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
TW201438739A (zh) 2009-03-20 2014-10-16 Genentech Inc 抗-ｈｅｒ抗體
CN107335062B (zh) 2010-06-08 2021-09-24 基因泰克公司 半胱氨酸改造的抗体和偶联物
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
CN112661848A (zh) * 2011-05-27 2021-04-16 豪夫迈·罗氏有限公司 双靶向
BR112014018005B1 (pt) 2012-02-15 2021-06-29 F. Hoffmann-La Roche Ag Uso de um complexo não covalente imobilizado
IN2014DN11157A (es) 2012-07-13 2015-10-02 Roche Glycart Ag
ES2746136T3 (es) 2013-04-29 2020-03-04 Hoffmann La Roche Anticuerpos modificados de unión a FcRn humano y procedimientos de uso
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
JP6744292B2 (ja) 2014-07-29 2020-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
CN107108724A (zh) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 半胱氨酸改造抗体和缀合物
AU2015345320A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Anti-IL-1beta antibodies and methods of use
WO2016075037A1 (en) * 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use in ophthalmology
EP3371217A1 (en) * 2015-11-08 2018-09-12 H. Hoffnabb-La Roche Ag Methods of screening for multispecific antibodies
CN109791149A (zh) * 2016-09-30 2019-05-21 豪夫迈·罗氏有限公司 用于功能分析多特异性分子的基于spr的双重结合测定法
MX2019012381A (es) * 2017-05-18 2020-01-23 Hoffmann La Roche Reduccion de reaccion secundaria relacionada con la aplicacion de un anticuerpo terapeutico.

Also Published As

Publication number Publication date
US20240101657A1 (en) 2024-03-28
EP3898671A1 (en) 2021-10-27
WO2020127873A1 (en) 2020-06-25
KR102652720B1 (ko) 2024-03-29
JP2022508393A (ja) 2022-01-19
PE20211294A1 (es) 2021-07-20
AR117468A1 (es) 2021-08-11
JP7114813B2 (ja) 2022-08-08
CL2021001616A1 (es) 2022-01-14
MX2021007421A (es) 2021-08-05
AU2019406712A1 (en) 2021-06-17
JP2023162345A (ja) 2023-11-08
KR20240042566A (ko) 2024-04-02
KR20210099053A (ko) 2021-08-11
BR112021012022A2 (pt) 2021-11-03
CO2021008755A2 (es) 2021-07-19
CA3123503A1 (en) 2020-06-25
TW202039552A (zh) 2020-11-01
AU2019406712B2 (en) 2024-08-22
JP7342212B2 (ja) 2023-09-11
US11130804B2 (en) 2021-09-28
US20200199214A1 (en) 2020-06-25
ZA202103643B (en) 2022-09-28
US20220041707A1 (en) 2022-02-10
SG11202106198YA (en) 2021-07-29
JP2022141933A (ja) 2022-09-29
IL283566A (en) 2021-07-29
CN113195531A (zh) 2021-07-30
US11866490B2 (en) 2024-01-09

Similar Documents

Publication Publication Date Title
MX2018016364A (es) Anticuerpos anti-pd-l1.
PH12017502019A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
EA201891040A1 (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CL2016001028A1 (es) Anticuerpos de alta afinidad y de agregación estable basados en dominios variables de vl y derivados de vhh.
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
EA201992756A2 (ru) Антитела против cd48 и их конъюгаты
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
JOP20190246A1 (ar) جسم مضاد أحادي النسيلة لـ pd-l1
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
SG10201801219VA (en) Anti-HER2 Antibodies
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
PH12020552270A1 (en) Anti-steap1 antigen-binding protein
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof